Reduced Gastrointestinal Complaints and Improved Quality of Life in Lung Transplant Recipients Converted From Mycophenolate Mofetil (MMF) to Myfortic (Enteric-coated Mycophenolate Sodium, Ec-mps).
Phase of Trial: Phase IV
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Lung transplant rejection
- Focus Adverse reactions
- 16 Feb 2018 Status changed from recruiting to discontinued.
- 24 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Jan 2010 New trial record